185 related articles for article (PubMed ID: 1394266)
1. Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index.
Asai A; Hoshino T; Edwards MS; Davis RL
Childs Nerv Syst; 1992 Aug; 8(5):273-8. PubMed ID: 1394266
[TBL] [Abstract][Full Text] [Related]
2. The proliferative potential of human ependymomas measured by in situ bromodeoxyuridine labeling.
Nagashima T; Hoshino T; Cho KG; Edwards MS; Hudgins RJ; Davis RL
Cancer; 1988 Jun; 61(12):2433-8. PubMed ID: 3284636
[TBL] [Abstract][Full Text] [Related]
3. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.
Shibuya M; Hoshino T; Ito S; Wacker MR; Prados MD; Davis RL; Wilson CB
Neurosurgery; 1992 Apr; 30(4):494-7; discussion 497-8. PubMed ID: 1584346
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme.
Ritter AM; Sawaya R; Hess KR; Levin VA; Bruner JM
Neurosurgery; 1994 Aug; 35(2):192-8; discussion 198. PubMed ID: 7969825
[TBL] [Abstract][Full Text] [Related]
5. Proliferative characteristics of juvenile pilocytic astrocytomas determined by bromodeoxyuridine labeling.
Ito S; Hoshino T; Shibuya M; Prados MD; Edwards MS; Davis RL
Neurosurgery; 1992 Sep; 31(3):413-8; discussion 419. PubMed ID: 1407423
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
Hoshino T; Ahn D; Prados MD; Lamborn K; Wilson CB
Int J Cancer; 1993 Feb; 53(4):550-5. PubMed ID: 8382191
[TBL] [Abstract][Full Text] [Related]
7. Spinal ependymomas. Part 2: Ependymomas of the filum terminale.
Klekamp J
Neurosurg Focus; 2015 Aug; 39(2):E7. PubMed ID: 26235024
[TBL] [Abstract][Full Text] [Related]
8. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
9. The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index.
Schröder R; Ploner C; Ernestus RI
Neurosurg Rev; 1993; 16(2):145-50. PubMed ID: 8345908
[TBL] [Abstract][Full Text] [Related]
10. Bromodeoxyuridine labeling study of intracranial meningiomas: proliferative potential and recurrence.
Lee KS; Hoshino T; Rodriguez LA; Bederson J; Davis RL; Wilson CB
Acta Neuropathol; 1990; 80(3):311-7. PubMed ID: 2399811
[TBL] [Abstract][Full Text] [Related]
11. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.
Hoshino T; Nagashima T; Cho KG; Murovic JA; Hodes JE; Wilson CB; Edwards MS; Pitts LH
Int J Cancer; 1986 Sep; 38(3):369-74. PubMed ID: 3527993
[TBL] [Abstract][Full Text] [Related]
12. Epithelial differentiation and proliferative potential in spinal ependymomas.
Takeuchi H; Kubota T; Sato K; Llena JF; Hirano A
J Neurooncol; 2002 May; 58(1):13-9. PubMed ID: 12160136
[TBL] [Abstract][Full Text] [Related]
13. Surgical outcomes in spinal cord ependymomas and the importance of extent of resection in children and young adults.
Safaee M; Oh MC; Mummaneni PV; Weinstein PR; Ames CP; Chou D; Berger MS; Parsa AT; Gupta N
J Neurosurg Pediatr; 2014 Apr; 13(4):393-9. PubMed ID: 24506340
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases.
Prayson RA
Am J Clin Pathol; 1998 Nov; 110(5):629-34. PubMed ID: 9802348
[TBL] [Abstract][Full Text] [Related]
15. Correlation of histopathological features and proliferative potential of gliomas.
Germano IM; Ito M; Cho KG; Hoshino T; Davis RL; Wilson CB
J Neurosurg; 1989 May; 70(5):701-6. PubMed ID: 2709110
[TBL] [Abstract][Full Text] [Related]
16. In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.
Hoshino T; Nagashima T; Murovic JA; Wilson CB; Edwards MS; Gutin PH; Davis RL; DeArmond SJ
J Neurosurg; 1986 Mar; 64(3):453-9. PubMed ID: 3950723
[TBL] [Abstract][Full Text] [Related]
17. [Proliferation kinetics of human brain tumors by in situ double labeling with bromodeoxyuridine and iododeoxyuridine].
Maeda T; Hoshino T
No To Shinkei; 1992 Sep; 44(9):821-5. PubMed ID: 1476811
[TBL] [Abstract][Full Text] [Related]
18. Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas.
Singh PK; Gutmann DH; Fuller CE; Newsham IF; Perry A
Mod Pathol; 2002 May; 15(5):526-31. PubMed ID: 12011257
[TBL] [Abstract][Full Text] [Related]
19. The clinical and prognostic relevance of grading in intracranial ependymomas.
Ernestus RI; Schröder R; Stützer H; Klug N
Br J Neurosurg; 1997 Oct; 11(5):421-8. PubMed ID: 9474274
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of localization and grading in intracranial ependymomas of childhood.
Ernestus RI; Schröder R; Stützer H; Klug N
Childs Nerv Syst; 1996 Sep; 12(9):522-6. PubMed ID: 8906366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
